Myovista iECG for Detecting Ischemic Heart Disease: Comparison With Computed Tomography Coronary Angiography
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01562730|
Recruitment Status : Unknown
Verified April 2012 by Angelo Auricchio, Cardiocentro Ticino.
Recruitment status was: Recruiting
First Posted : March 26, 2012
Last Update Posted : May 1, 2012
|Condition or disease|
|Coronary Artery Disease|
Non-invasive identification of patients with coronary artery disease using a single, highly reliable technique is challenging. Computed tomography coronary angiography (CTCA) has emerged as a patient-friendly, accurate diagnostic tool. Compared to invasive coronary angiography, the sensitivity and specificity of CTCA for detecting significant coronary stenosis has been reported to be higher than 90%. Moreover, CTCA allows the detection of nonobstructive coronary plaques (CAPs). However, the advantage of CTCA is frequently reduced by significantly higher radiation exposure.
New MyoVista™ iECG technology
The MyoVista™ (Heart Test Laboratories Inc., Colleyville, TX, USA) is a novel electrocardiographic device. The clinical set up of MyoVista™ is identical to that of a traditional 12-lead ECG but it acquires and processes signal information in a way that permits much greater resolution of the electrical activity associated with the myocardium (iECG). This technology property of Heart Test Laboratories allows analysis of the entire myocardium and provides visual indicators and waveforms for clinical evaluation.
MyoVista™ technology has been so far validated in cohorts of Asian patients undergoing a clinically-indicated coronary angiography. These studies showed high positive and negative predictive values for identification of CAD. In addition, preliminary studies performed in the USA suggest a potential incremental value of iECG over routine surface ECG as a screening tool for detection of subclinical LV dysfunction and latent cardiovascular risk.
The aim of this prospective controlled evaluation is to assess
- the sensitivity, specificity, and predictive value of MyoVista™ iECG in consecutive individuals without any history of cardiovascular disease undergoing a clinically indicated Computed Tomography Coronary Angiography (CTCA) in detecting Coronary Artery Plaque (CAP) and/or Coronary Artery Disease (CAD) (Group 1);
- the sensitivity, specificity, and predictive value of MyoVista™ iECG in consecutive individuals with history of cardiovascular disease undergoing a clinically indicated CTCA in detecting the extent of CAP or CAD (Group 2);
- whether MyoVista™ iECG abnormality is a better predictor of traditional risk factors to prevalence of CAP in individuals without history of cardiovascular disease.
|Study Type :||Observational|
|Estimated Enrollment :||1000 participants|
|Official Title:||Incremental Value of Signal Processed Surface Electrocardiography (IECG) for Detecting Ischemic Heart Disease: Comparison With Computed Tomography Coronary Angiography (CTCA)|
|Study Start Date :||April 2012|
|Estimated Primary Completion Date :||April 2013|
|Estimated Study Completion Date :||April 2013|
No previous cardiovascular disease
Individuals without any history of cardiovascular disease
Previous cardiovascular disease
Individuals with history of cardiovascular disease
- Comparison between Myovista iECG findings and CTCA (gold standard) results [ Time Frame: one day ]Comparison of findings from the two methods will be made to demonstrate that Myovista iECG is equally effective as CTCA in predicting CAPs and/or CAD in individuals with or without history of cardiovascular disease, in terms of sensitivity, specificity and predictive value
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01562730
|Contact: Angelo Auricchio, MD PhD FESC||+41 91 805 3340||Angelo.Auricchio@cardiocentro.org|
|Fondazione Cardiocentro Ticino||Recruiting|
|Lugano, Switzerland, CH-6900|
|Contact: Angelo Auricchio, MD PhD FESC +41 91 805 3340 Angelo.Auricchio@cardiocentro.org|
|Principal Investigator: Angelo Auricchio, MD PhD FESC|
|Sub-Investigator: François Regoli, MD.|
|Sub-Investigator: Marta Aceña, MD|
|Principal Investigator:||Angelo Auricchio, MD PhD FESC||Fondazione Cardiocentro Ticino|